GETI.B

188.3

-1.15%↓

EKTA.B

55.7

-2.28%↓

ATT

99.6

-1.97%↓

AMBEA

132.9

+0.3%↑

ARJOB

25.88

-0.61%↓

GETI.B

188.3

-1.15%↓

EKTA.B

55.7

-2.28%↓

ATT

99.6

-1.97%↓

AMBEA

132.9

+0.3%↑

ARJOB

25.88

-0.61%↓

GETI.B

188.3

-1.15%↓

EKTA.B

55.7

-2.28%↓

ATT

99.6

-1.97%↓

AMBEA

132.9

+0.3%↑

ARJOB

25.88

-0.61%↓

GETI.B

188.3

-1.15%↓

EKTA.B

55.7

-2.28%↓

ATT

99.6

-1.97%↓

AMBEA

132.9

+0.3%↑

ARJOB

25.88

-0.61%↓

GETI.B

188.3

-1.15%↓

EKTA.B

55.7

-2.28%↓

ATT

99.6

-1.97%↓

AMBEA

132.9

+0.3%↑

ARJOB

25.88

-0.61%↓

Home・Akciju saraksts・Vivesto AB

Vivesto AB

Slēgts

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi
By Trading Economics
Ienākumi	-1.9M -9.1M
EPS	-0.015
Darbinieki	4
EBITDA	-1.8M -8.9M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.9M 49M
Iepriekšējā atvēršanas cena	0
Iepriekšējā slēgšanas cena	0

Vivesto AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026. g. 13. marts 19:08 UTC

Galvenie ziņu notikumi

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

2026. g. 15. marts 23:45 UTC

Tirgus saruna

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

2026. g. 15. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

2026. g. 15. marts 23:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

2026. g. 15. marts 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

2026. g. 15. marts 22:37 UTC

Tirgus saruna

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

2026. g. 15. marts 22:18 UTC

Tirgus saruna

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 03:00 UTC

Galvenie ziņu notikumi

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

2026. g. 14. marts 15:00 UTC

Galvenie ziņu notikumi

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026. g. 14. marts 02:03 UTC

Peļņas

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026. g. 14. marts 01:32 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026. g. 14. marts 00:29 UTC

Iegādes, apvienošanās, pārņemšana

13D Filings -- Barrons.com

2026. g. 13. marts 22:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026. g. 13. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026. g. 13. marts 22:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026. g. 13. marts 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 13. marts 20:02 UTC

Tirgus saruna

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026. g. 13. marts 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026. g. 13. marts 19:35 UTC

Galvenie ziņu notikumi

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Vivesto AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.